Prostate cancer remains a significant public health problem. The current approach with prostate-specific antigen (PSA)-based screening has questionable effects on prostate cancer–specific mortality ...

Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man's risk of being diagnosed with prostate cancer from around 5--9 percent to around 4-6 percent during up to ...

This article presents background information and highlights key findings from a managed care perspective related to enlarged prostate (EP) in Medicare-eligible patients. This article does not provide ...

A study evaluates the risk for osteoporosis or osteopenia associated with 5-alpha reductase inhibitors in women with two ...

Men who take 5-alpha-reductase inhibitors while on active surveillance for prostate cancer are less likely to experience cancer progression, according to a new study Use of 5-alpha-reductase ...

: To evaluate the likelihood of alphaadrenergic antagonist (alpha-blocker) discontinuation in combination with dutasteride or finasteride among patients aged =65 years with enlarged prostate. Methods ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. While 5-alpha-reductase inhibitor use did not increase ...